Coronary disease & ACSMeta-analysis
Colchicine for secondary prevention of vascular events: a meta-analysis of trials
- Systematic review and meta-analysis of randomised trials
- study-level
- fixed-effect inverse variance model
Authors' conclusion
In patients with prior coronary disease or stroke, colchicine reduced the composite of cardiovascular death, myocardial infarction, or stroke by 12%.
Study context
- Population
- Secondary-prevention atherosclerotic CVD population (known CAD or stroke)
- Participants
- 30,659 participants · 9 trials
- Comparison
- Colchicine vs no colchicine
- Colchicinen = 15,255
- No colchicinen = 15,404reference
- Outcome
- Composite of:
- CV death
- MI
- Stroke
Pooled result
CV death, MI or stroke
Relative risk
0.88
95% CI 0.81–0.95
P = 0.002
Colchicine vs No colchicine
RR 0.88 (95% CI 0.81–0.95); P = 0.002
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| CV death | 0.94 (0.78–1.13) | P = 0.5 | |
| MI | 0.84 (0.73–0.97) | P = 0.016 | |
| Stroke | 0.90 (0.80–1.02) | P = 0.09 | |
| 0.512Relative risk (log scale) |
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Hospitalization for gastrointestinal events | 1.35 (1.10–1.66) | P = 0.004 | |
| 0.512Relative risk (log scale) |
Hospitalization for pneumonia, new cancers, non-CV death
- No increase in hospitalization for pneumonia, newly diagnosed cancers or non-CV death
Original publication
Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur Heart J. Published 2 May 2025. doi:10.1093/eurheartj/ehaf210
Summarised from the published abstract; every number is checked against it